In line with these results, SET-siRNA treatments, JAK2 inhibition, and PP2A reactivation with specific PADs (PP2A-activating drugs) such as FTY-720 or Forskolin support the critical role of PP2A reactivation in CML leukemogenesis [97,98]. The gene discussed is PTPA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.